With ~700,000 new cases each year, HCC constitutes the second most common cause of cancer mortality. HCC, a form of liver cancer, constitutes a significant unmet medical need since most patients are diagnosed at a late stage of the disease, and present treatments bring limited benefits in terms of overall survival rate. The purpose of Project CT-01 is to develop, based on targeted protein degradation technology, a drug candidate which will stop the progress of hepatocellular carcinoma (HCC) and potentially offer significant benefits for patients. This compelling efficacy data, coupled with the unique degradation profile announced today, support our growing confidence in the strong scientific, medical and competitive value of the project."Ĭaptor Therapeutics plans to advance CT-01 towards Investigational New Drug Application (IND)-enabling studies and to initiate clinical trials in 2023. "We have already reported compelling pre-clinical data showing that CT-01 candidate compounds induced strong tumor regression in a Hep 3B2.1-7 mouse model of human HCC. "The CT-01 targets fundamentally contribute to cancer development and their elimination has potent therapeutic potential in the treatment hepatocellular carcinoma as well as several other malignances," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics. SALL4 is a transcription factor expressed in the human fetal liver and silenced in adults but often re-expressed in HCC patients, which correlates with poor prognosis. There is a demonstrated link between GSPT1 degradation and antitumor activity. GSPT1 is a protein involved in the termination of translation, a process in which ribosomes synthesize proteins after the transcription of DNA to RNA. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces the molecular targets of one of its core pipeline projects designated CT-01, which is focused on the development of TPD therapy for hepatocellular carcinoma (HCC).Ĭompelling in-vitro and in-vivo preclinical data demonstrate that CT-01 candidate compounds induce degradation of Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1), Sal-like protein 4 (SALL4) and another undisclosed neo-substrate with essential function in tumorigenesis. WROCLAW, Poland, Ap(GLOBE NEWSWIRE) - Captor Therapeutics S.A. CT-01 on track to enter clinical development in 2023.Compelling pre-clinical data generated demonstrating HCC tumor regression.The unique degradation profile supports the strong competitive potential of the program.CT-01 compounds induce degradation of GSPT1, SALL4 and another as yet undisclosed neo-substrate.The content is current as at date of publication. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. Past performance does not necessarily indicate a financial product’s future performance. You should consider the advice in light of these matters and if applicable the relevant Product Disclosure Statement before making any decision to invest. To obtain advice tailored to your situation, contact a financial advisor. For more information refer to our Financial Services Guide. Any general advice has been provided without reference to your investment objectives, financial situations or needs. To the extent any content is general advice, it has been prepared by Morningstar Australasia Pty Ltd (ABN 95 090 665 544, AFSL: 240892). Additionally, important disclosures regarding these research reports, methodologies and Morningstar can be found under the legal section on this site.
CAPTOR THERAPEUTICS FULL
Full research reports are available from Morningstar.
Certain content provided may constitute a summary or extract of a full research report. Neither Morningstar, its affiliates, nor the content providers are responsible for any investment decisions, damages or losses resulting from, or related to, the content, data and analyses or their use. The content provided does not constitute investment advice, is provided solely for information purposes, is not an offer to buy or sell a security, and is not warranted to be correct, complete or accurate. Information on this site is intended for Australian users only.
0 kommentar(er)
